THU0694 BRAZILIAN SJÖGREN’S SYNDROME REGISTRY (BRASS): A LARGE BRAZILIAN MULTICENTRIC COHORT OF PRIMARY SJÖGREN’S SYNDROME

Background Primary Sjogren’s syndrome (pSS) is an orphan systemic autoimmune disease with no treatment based on evidence 1 . There is an international effort for multicentric registries for getting information about phenotypes, complication, response of treatment, and biobank consortium. Objectives To describe the creation of the Brazilian Sjogren’s Syndrome Registry (BRASS) and present the preliminary data. Methods BRASS is supported by Brazilian Society of Rheumatology (SBR) and is including patients from all regions of the country. Recruitment started in 2018 and is due to be completed in 2024. We are including patients with pSS according to AECG 2002 or ACR-EULAR 2016 classification criteria. All patients are being assessed for disease activity (ESSDAI), disease damage (SSDDI), symptoms assessment (ESSPRI), fatigue (FACIT-Fatigue), anxiety and depression (HADS), sleepiness (Epworth Sleepiness Scale), physical activity (IPAQ-SF) and quality of life (EQ-5D). In addition, demographics, immunological tests, unstimulated whole salivary flow (UWSF), salivary gland biopsy (SGB), comorbidities, treatment and complications such as cancer and cardiovascular risk assessment are being collected. Results There are currently 10 centers across the Brazil and 248 patients were evaluated until now. Most patients were female, white (45%) or mixed (38.3%), with the mean of the disease duration of 8 years. ESSDAI at baseline was 6.62±6.37 and currently is 4.21±5.16 (p Conclusion ESSDAI has decreased over time and more than half of patients are on hydroxychloroquine, immunosuppressant or biological therapy. Further analysis is needed to understand whether the reduction in ESSDAI reflects the natural course of the disease or greater access to treatment. BRASS Registry will be important to enhance research and to develop public health planning. References [1] Valim V et al. Recommendations for the treatment of Sjogren’s syndrome. Rev Bras Reumatol 55:446–57, 2015. Disclosure of Interests None declared